In addition, recent studies from our lab demonstrated remarkable synergistic anticancer activity for the combination of crizotinib, a MET inhibitor, with the endocrine drugs tamoxifen and fulvestrant in different breast cancer cell lines in vitro [46, 47]. This evidence concerns the gene MET and breast cancer.